Our Research

Our research to help people with PF and other exposure-related conditions is ongoing. These research programs include double-blind, placebo-controlled clinical trials for natural, supplemental, and alternative therapies. Several publications are available on this page. Please contact us if you have any questions or would like to share your thoughts. If you’re a researcher, we’d love to hear from you!

Potential of the Combination of a Systemic Enzyme Complex and Probiotics administration to Combat COVID-19: A Randomized Open Label Prospective Analysis.

Published February 8th, 2021.

Objective: We investigated the safety and efficacy of the health supplements ImmunoSEB (systemic enzyme complex) and ProbioSEB CSC3 (probiotic complex) as supplemental therapy in confirmed mild to moderate COVID-19 patients.

Conclusion: The present study concludes that supplemental therapy with ImmunoSEB + ProbioSEB CSC3 accelerates clinical improvement in mild to moderate COVID-19 patients. While there is no vaccine or specific drug to completely cure SARS CoV-2 infection, the proposed supplemental therapy could be a potential tool to aid in the recovery of COVID-19 patients.

Management of Post COVID-19 Fatigue using Systemic Enzymes and Probiotics - Case Series.

Published February 23rd, 2021.

Objective: To evaluate the potential of health supplements ImmunoSEB (systemic enzyme complex) and ProbioSEB CSC3 (probiotic complex) to aid in the recovery of COVID-19 patients, many of whom continue to experience severe fatigue several months after initial infection. 

Conclusion: The present cases demonstrate that a 14 days supplementation of ImmunoSEB + ProbioSEB CSC3 significantly reduces post-COVID-19 fatigue in patients, with all patients reporting no more than usual or less than usual fatigue at the end of the 14 days treatment period.

Serratiopeptidase: Insights into the therapeutic applications

Published October 17th, 2020.

Objective: To explore the available literature on serratiopeptidase, to review the details of its therapeutic use, and to provide scientific details for existing applications based on available in vitro, in vivo, and clinical studies. 

Conclusion: There are some strong evidences regarding the efficacy of serratiopeptidase in anti-inflammatory, fibrinolytic, anti-biofilm, analgesic, and anti-edemic applications. However data on safety, tolerability, and its mechanism of action need detailing.

Effects of Systemic Enzyme Supplements on Symptoms and Quality of Life in Patients with Pulmonary Fibrosis—A Pilot Study

Published November 5, 2021.

Objective: To evaluate the effects of systemic enzymes in relieving symptoms associated with PF and improving quality of life

Conclusion: Serracor‐NK and Serra Rx improve symptoms, as well as mental and physical wellbeing and health-related quality of life (HRQL) in patients with PF.

PulmonaryFibrosisNow.org